title: Update on the treatment of genital warts.
abstract: This review summarizes new treatments from the last seven years employed for the treatment of genital warts caused by human papillomavirus (HPV). Imquimod 3.75% is a new agent with fewer side effects and perhaps a better dosing schedule than imquimod 5%, but is not more effective. Sinecatechins/Polyphenon E 15%, a novel extract from green tea can be effective against genital warts but requires three times a day dosing and is not more effective than existing treatments; the treatment course is 12-16 weeks. Photodynamic therapy combined with other destructive modalities might increase the cure rate for genital warts. The quadrivalent vaccine against HPV 6, 11, 16, 18 is decreasing the incidence of warts in the western world but the evidence does not support vaccination as a treatment for those already infected by HPV. Hyperthermia and immunomodulators might be positive additions to the armamentarium of clinicians. In sum, there are new tools that physicians can use but none is really a great advance over what was available a decade ago.
authors.affiliation: Weill Cornell Medical College, New York, NY, USA. Scheinfeld@earthlink.net
authors.forename: Noah
authors.initials: N
authors.lastname: Scheinfeld
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D015197:Carcinogenicity Tests; D002392:Catechin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004564:Electrocoagulation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D019695:Glycyrrhizic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D006979:Hyperthermia, Induced; D000077271:Imiquimod; D007167:Immunotherapy; D015994:Incidence; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D053918:Papillomavirus Vaccines; D010778:Photochemotherapy; D008517:Phytotherapy; D015995:Prevalence; D055502:Secondary Prevention; D014481:United States / Q000453:epidemiology
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D003879:Dermatologic Agents; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C527126:green tea extract polyphenone E; D019695:Glycyrrhizic Acid; D002392:Catechin; D000077271:Imiquimod; C472086:polyphenon E